Європейський Союз - естонська - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - emapalumab - immune system diseases - gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (hlh).

Естонія - естонська - Ravimiamet

krka d.d. novo mesto - amoksitsilliin - dispergeeruv tablett - 1000mg 8tk; 1000mg 16tk; 1000mg 12tk; 1000mg 20tk; 1000mg 6tk

Естонія - естонська - Ravimiamet

krka d.d. novo mesto - amoksitsilliin - dispergeeruv tablett - 750mg 30tk; 750mg 12tk; 750mg 16tk; 750mg 20tk

Естонія - естонська - Ravimiamet

venus pharma gmbh - imipeneem+tsilastatiin - infusioonilahuse pulber - 500mg+500mg 10tk; 500mg+500mg 5tk

Європейський Союз - естонська - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriaas - immunosupressandid - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Естонія - естонська - Ravimiamet

ideal trade links uab - piperatsilliin+tasobaktaam - infusioonilahuse pulber - 4000mg+500mg 24tk; 4000mg+500mg 12tk

Європейський Союз - естонська - EMA (European Medicines Agency)

ucb pharma sa - certolizumab pegol - crohni tõbi - immunosupressandid - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia saab antud monotherapy juhul, talu metotreksaati või kui jätkuv ravi metotreksaadi on kohatu. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.